Revolution Medicines, Inc. (RVMDW) stock
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Revolution Medicines, Inc. reported revenue of $0 for fiscal 2025. Free cash flow was -$1.23B. At the latest close the market valued the company at $41.00B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $41.00B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 15.73
- Dividend yield
- –
- Free cash flow yield
- -3.00%
Fundamentals
- Revenue
- $0
- Net income
- -$1.77B
- EPS, diluted
- -$8.84
- Free cash flow
- -$1.23B
- Book value per share
- $12.36
- Diluted shares
- 211M
Trading
- Next earnings
- Nov 4, 2026 (estimated, after the close)
- Previous close
- $9.63
- Open
- $9.65
- Day's range
- $9.45 – $9.81
- Volume
- 5,614
- Average volume (20 days)
- 20,239
- Beta (5 years)
- 1.37
- 52-week range
- $56.66 – $224.31
- RSI (14 days)
- 48.7
- Volatility (1 year)
- 66.6%
- Relative volume
- 0.51×
- WACC
- 11.8%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | RVMDW | S&P 500 | Difference | RVMDW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.2% | -0.9% | −13.3 pts | ||
| 3 months | -0.7% | +2.1% | −2.9 pts | ||
| Year to date | +943.7% | +11.7% | +932.0 pts | ||
| 1 year | +2306.2% | +12.4% | +2293.8 pts |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Revolution Medicines filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Revolution Medicines
Biological Products, (No Diagnostic Substances)
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapeutics for cancer patients. The business concentrates on the discovery and clinical advancement of novel drug candidates aimed at critical oncogenic pathways driving cancer progression. Because the company currently has no products approved for commercial sale, its pipeline candidates remain under preclinical and clinical investigation. Consequently, its primary end beneficiaries are oncology patients, alongside research collaborators, licensing organizations, and healthcare institutions engaged in precision oncology drug development.
Company profile, executives and historyRevolution Medicines stock: common questions
What is Revolution Medicines's stock price?
RVMDW closed at $9.81 on Oct 30, 2026, up 1.82% on the day. Over the past 52 weeks it traded between $56.66 and $224.31.
What is Revolution Medicines's market cap?
Revolution Medicines was worth $41.00B at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is RVMDW's P/E ratio?
Revolution Medicines lost money over the twelve months to Jun 30, 2026 (diluted EPS -$8.84), so it has no meaningful P/E ratio.
How much revenue does Revolution Medicines make?
Revolution Medicines reported revenue of $0 for fiscal 2025.
Does Revolution Medicines pay a dividend?
No. Revolution Medicines has not paid a cash dividend over the last twelve months.
When does Revolution Medicines report earnings next?
Revolution Medicines is expected to report Q3 FY2026 results on Nov 4, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has RVMDW stock performed over the past year?
Including dividends, RVMDW returned +2306.2% over the past year, against +12.4% for the S&P 500.
Who are Revolution Medicines's competitors?
Companies most similar to Revolution Medicines by business, industry and size include RLAY, CRIS, CRDF, CLDI, CERO.